Introduction The recent development of radioimmunotherapy (RIT) is a significant step forward in the treatment of patients with low-grade and follicular non-Hodgkin’s lymphoma, a malignancy that is well known to be inherently radiosensitive. Highly convincing efficacy [1–3] and safety [4] data are now available to support the benefits of RIT in follicular lymphoma. In addition, RIT offers signi...

The radiosensitivity of lymphomas as well as the local targeted delivery of high doses of radiation make radioimmunotherapy (RIT) an attractive therapeutic option. RIT is indeed an underestimated tool. In follicular lymphoma (FL), RIT represents one of the most effective single agents. The two most commonly used radioimmunoconjugates are Y-ibritumomab tiuxetan (Zevalin ) and I-tositumomab, both...